Eli Lilly, BI form drug pact in stress urinary incontinence. (Life Sciences).(Boehringer Ingelheim GmbH)

Chemical Market Reporter, December, 2002 by Krause, Carey

ELI LILLY and Company has inked a long-term agreement with Boehringer Ingelheim GmbH (BI) to jointly commercialize duloxetine, a key player in Lilly's crowded pipeline. The pact, Lilly's first major copromotion deal for an in-house product, lays the groundwork for mining a potentially lucrative yet untapped market, stress urinary incontinence (SUI.) The deal also fortifies Lilly's footprint in Europe, which is somewhat weaker than its US competitors' and provides near-term earnings ahead of new product launches.

Analysts estimate duloxetine will reach sales of $1 billion by 2005. Lilly and BI will commercialize duloxetine to treat SUI on a worldwide basis, excluding Japan. Lilly filed duloxetine for SUI in the US in the fourth quarter of 2002. A...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.